Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

A composition for managing the weight of a subject, wherein the composition includes at least one high-viscosity, resorbable, biocompatible material, intended to be injected into the submucosal space of the digestive tract of a subject and thus creating a long-lasting raising of the corresponding mucosa is disclosed. Also disclosed is a kit including a composition according to the invention and structure for injecting the composition. Finally, the disclosure also relates to the use of a composition according to the invention for managing the weight of a subject.

A composition for managing the weight of a subject, wherein the composition includes at least one high-viscosity, resorbable, biocompatible material, intended to be injected into the submucosal space of the digestive tract of a subject and thus creating a long-lasting raising of the corresponding mucosa is disclosed. Also disclosed is a kit including a composition according to the invention and structure for injecting the composition. Finally, the disclosure also relates to the use of a composition according to the invention for managing the weight of a subject.

The present disclosure features useful compositions and methods to treat repeat expansion disorders, e.g., in a subject in need thereof. In some aspects, the compositions and methods described herein are useful in the treatment of disorders associated with MLH3 activity.

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the combined use of a PD-1 inhibitor, a TGFβ inhibitor, an ATM inhibitor and radiation to treat cancer.

Disclosed are a benzimidazole derivative of formula (I), or an isomer, a pharmaceutically-acceptable salt, or a prodrug thereof, and a preparation thereof. An application of the benzimidazole derivative in the treatment of tumors is further provided.

##STR00001##

Disclosed are a benzimidazole derivative of formula (I), or an isomer, a pharmaceutically-acceptable salt, or a prodrug thereof, and a preparation thereof. An application of the benzimidazole derivative in the treatment of tumors is further provided.

##STR00001##

The present invention relates to methods of treating HBV, COVID-19 or SARS-CoV-2 infection in a human patient, wherein the methods comprise administration of a therapeutically effective amount of a TLR7 agonist, or a pharmaceutically acceptable salt thereof.

The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat and/or prevent hepatitis B virus (HBV) infections in a patient.